London: Scientists have developed a new injection that could limit the devastating consequences of heart attacks and strokes, a breakthrough which they say could soon revolutionise treatments for cardiovascular diseases. An international team led by researchers at University of Leicester said their `achievement` has also potential usage in transplant surgery. According to the researchers, who detailed their study in the Proceedings of the National Academy of Sciences (PNAS), they first identified an enzyme, called MASP-2, which is a key component of the lectin pathway of complement activation – a component of the innate immune system.
"Limiting this inflammatory response in oxygen-deprived tissues could dramatically improve outcomes and survival in patients suffering heart attacks or strokes." For more than seven years, the University of Leicester team has been working closely with Omeros Corporation in Seattle to develop therapeutic antibodies for research andclinical applications. Omeros holds exclusive worldwide intellectual property rights to the MASP-2 protein, all therapeutic antibodies targeting MASP-2 and all methods for treating disorders byinhibiting MASP-2. The company has already begun manufacturing scale-up of an antibody for use in human clinical trials. The first clinical trials evaluating Omeros` human antibody in myocardial infarction patients will be conducted soon in the Leicester Biomedical Research Unit. PTI
INS Kuthar mishap: Navy orders probe
TRAI Amendment Bill passed in Lok Sabha
Govt slaps $579 mn additional penalty on RIL
UPSC aspirants protest outside Rajnath Singh`s residence